6-K 1 form6-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of June 2023

 

Commission File Number 001-41231

 

TC BIOPHARM (HOLDINGS) PLC

(Translation of registrant’s name into English)

 

Maxim 1, 2 Parklands Way

Holytown, Motherwell, ML1 4WR

Scotland, United Kingdom

+44 (0) 141 433 7557

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

  Form 20-F Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 
 

 

Results of Annual General Meeting

 

On June 29, 2023, TC BioPharm (Holdings) plc (“TC BioPharm” or the “Company”) held its 2023 Annual General Meeting (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on June 7, 2023 were duly proposed and passed on a poll.

 

The matters presented for a vote and the related results are as follows:

 

Ordinary Resolutions  Votes For  

Votes

Against

  

Votes

Abstained

 
             

Resolution 1: Report and accounts

To receive the Company’s annual report and audited financial statements for the year ended 31 December 2022.

   736,865    62,390    10,198 
                

Resolution 2: Directors’ remuneration report

To receive and approve the Directors’ Remuneration Report for the year ended 31 December 2022.

   733,914    68,548    6,991 
                

Resolution 3: Directors’ remuneration policy

To receive and approve the Directors’ Remuneration Policy.

   718,162    87,120    4,171 
                

Resolution 4: Appointment of auditor

To appoint Ecovis Wingrave Yeats LLP as auditor of the Company (“Ecovis”), to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company at which the Company’s financial statements are laid before the Company.

   729,834    75,739    3,880 
                

Resolution 5: Remuneration of auditor

To authorise the Audit Committee to determine the remuneration of the Auditor.

   739,407    65,223    4,825 

 

The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on June 7, 2023 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on June 7, 2023.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  TC BIOPHARM (HOLDINGS) PLC
     
Date: June 29, 2023 By: /s/ Martin Thorp
    Martin Thorp
    Chief Financial Officer